RealTime Dynamix™: Hyperkalemia, June 2016
The sixth monthly update on the launch of Veltassa and the evolution of the Hyperkalemia market provided by 101 Nephrologists.
Download Report Overview
About Spherix Global Insights
Spherix Global Insights is a newly established business intelligence and market research company headquartered in Cambridge, MA with EU offices in Zug, Switzerland. We specialize in renal, autoimmune, neurologic and rare disease markets.
For more information contact:
Telephone: (800) 661-0571
Email: info@spherixglobalinsights.com
www.spherixglobalinsights.com
Related Posts
-
RHEUMATOLOGISTS PLAN TO INCREASE THEIR USE OF PFIZER’S XELJANZ, JANSSEN’S SIMPONI AND ROCHE’S ACTEMRA IN THE NEXT MONTH
Over 40% of current Xeljanz users expect to increase use, with many rheumatologists initiating the agent prior to biologics, according…
-
Despite An Increase in Psoriatic Arthritis Patients Initiated on Cosentyx Over the Past Three Months, the User Base for Novartis’ IL-17 Inhibitor Has Remained Stable
Download Report Overview ZUG, Switzerland, Nov. 2, 2016 /PRNewswire/ -- A recent study of nearly 100 surveyed US rheumatologists reveals…
-
Dupixent Delivers… and Sanofi-Regeneron Ushers in a New Era of Atopic Dermatitis (AD) Treatment
According to Spherix Global Insights, at just one month post-launch, nearly one-third of surveyed dermatologists (n=101) have prescribed Dupixent, although…
